Answers are grounded in this paper and cite their sources.
Helodermatid exendins provide a framework for examining how venom peptide diversification relates to receptor recognition and biomedical potential. This narrative review integrates published evolutionary models with sequence, structural, and pharmacological evidence for helospectins, helodermin, and exendins-3 and -4. A complementary maximum-likelihood analysis compares 17 precursor-length records and 18 peptide-core records, distinguishing characterized Heloderma sequences from homology-based predictions. Precursor and signal/propeptide analyses support the exendin-3/exendin-4 pair, while the peptide-core analysis supports the helospectin/helodermin pair, revealing region-dependent sequence relationships. We examine how amino acid substitutions, C-terminal variation, and post-translational modifications relate to interactions with class B1 G protein-coupled receptors. Helospectins exhibit species-dependent receptor preferences, while comparisons between exendin-3 and exendin-4 associate limited N-terminal variation with distinct pharmacological profiles in historical pancreatic assays. These observations connect molecular diversity with experimental pharmacology while keeping sequence relationships distinct from receptor selectivity and biological function. Exendin-4-derived therapeutics and imaging agents illustrate the biomedical development of a venom peptide scaffold. Together, the literature synthesis and comparative sequence analysis provide a clearer basis for investigating how exendin variation influences receptor activity and guides the development of venom-derived peptides.
No takes yet. Share an insight, caveat, or question.
Zataraín-Palacios et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: